Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1982 1
1985 1
1989 1
1990 1
1991 2
1992 5
1993 1
1994 3
1995 3
1996 5
1997 4
1998 13
1999 7
2000 17
2001 19
2002 24
2003 16
2004 29
2005 41
2006 52
2007 67
2008 77
2009 73
2010 77
2011 92
2012 95
2013 116
2014 121
2015 109
2016 95
2017 117
2018 114
2019 142
2020 183
2021 193
2022 222
2023 198
2024 204
2025 249
2026 49

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,468 results

Results by year

Filters applied: . Clear all
Page 1
Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial.
Cheng J, Gao C, Ala-Jaakkola R, Forssten SD, Saarinen M, Hibberd A, Ouwehand AC, Ibarra A, Li D, Nordlund A, Wang Y, Shen X, Peng H, Wan X, Meng X. Cheng J, et al. JAMA Netw Open. 2024 Oct 1;7(10):e2436888. doi: 10.1001/jamanetworkopen.2024.36888. JAMA Netw Open. 2024. PMID: 39356506 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the potential benefit of Bifidobacterium animalis subsp lactis HN019 on constipation, expressed as complete spontaneous bowel movements (CSBMs). ...INTERVENTION: Participants were randomized to receive probiotic (B lactis HN019, …
OBJECTIVE: To evaluate the potential benefit of Bifidobacterium animalis subsp lactis HN019 on constipation, expressed …
Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial.
Zhang Q, Li G, Zhao W, Wang X, He J, Zhou L, Zhang X, An P, Liu Y, Zhang C, Zhang Y, Liu S, Zhao L, Liu R, Li Y, Jiang W, Wang X, Wang Q, Fang B, Zhao Y, Ren Y, Niu X, Li D, Shi S, Hung WL, Wang R, Liu X, Ren F. Zhang Q, et al. Nat Commun. 2024 Jan 3;15(1):227. doi: 10.1038/s41467-023-44292-x. Nat Commun. 2024. PMID: 38172093 Free PMC article. Clinical Trial.
This randomized controlled clinical trial (Chinese Clinical Trial Registry, ChiCTR2000041430) assigned 200 FD patients to receive placebo, positive-drug (rabeprazole), or Bifidobacterium animalis subsp. lactis BL-99 (BL-99; low, high doses) for 8-week. The pr …
This randomized controlled clinical trial (Chinese Clinical Trial Registry, ChiCTR2000041430) assigned 200 FD patients to receive placebo, p …
Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial.
Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Ibarra A, et al. Gut Microbes. 2018;9(3):236-251. doi: 10.1080/19490976.2017.1412908. Epub 2018 Feb 8. Gut Microbes. 2018. PMID: 29227175 Free PMC article. Clinical Trial.
Bifidobacterium animalis subsp. lactis HN019 (HN019) ameliorates chronic idiopathic constipation. ...
Bifidobacterium animalis subsp. lactis HN019 (HN019) ameliorates chronic idiopathic constipation. ...
The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12( ) in infant colic: A randomised, double blind, placebo-controlled trial.
Nocerino R, De Filippis F, Cecere G, Marino A, Micillo M, Di Scala C, de Caro C, Calignano A, Bruno C, Paparo L, Iannicelli AM, Cosenza L, Maddalena Y, Della Gatta G, Coppola S, Carucci L, Ercolini D, Berni Canani R. Nocerino R, et al. Aliment Pharmacol Ther. 2020 Jan;51(1):110-120. doi: 10.1111/apt.15561. Epub 2019 Dec 3. Aliment Pharmacol Ther. 2020. PMID: 31797399 Free PMC article. Clinical Trial.
AIMS: To assess the rate of infants with a reduction of 50% of mean daily crying duration after 28 days of intervention with the probiotic Bifidobacterium animalis subsp. lactis BB-12( ) (BB-12). Secondary outcomes were daily number of crying episodes, sleep …
AIMS: To assess the rate of infants with a reduction of 50% of mean daily crying duration after 28 days of intervention with the probiotic …
Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial.
Lai H, Li Y, He Y, Chen F, Mi B, Li J, Xie J, Ma G, Yang J, Xu K, Liao X, Yin Y, Liang J, Kong L, Wang X, Li Z, Shen Y, Dang S, Zhang L, Wu Q, Zeng L, Shi L, Zhang X, Tian T, Liu X. Lai H, et al. Gut Microbes. 2023 Jan-Dec;15(1):2197837. doi: 10.1080/19490976.2023.2197837. Gut Microbes. 2023. PMID: 37078654 Free PMC article. Clinical Trial.
Intervention: A: polydextrose; B: psyllium husk; C: wheat bran + psyllium husk; D: Bifidobacterium animalis subsp. lactis HN019 + Lacticaseibacillus rhamnosus HN001; Placebo: maltodextrin. ...Daily supplement of three prebiotic formulas with dietary fibers (p …
Intervention: A: polydextrose; B: psyllium husk; C: wheat bran + psyllium husk; D: Bifidobacterium animalis subsp. lactis …
Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
Martoni CJ, Srivastava S, Leyer GJ. Martoni CJ, et al. Nutrients. 2020 Jan 30;12(2):363. doi: 10.3390/nu12020363. Nutrients. 2020. PMID: 32019158 Free PMC article. Clinical Trial.
Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, Lactobacillus acidophilus DDS-1 (1 10(10) CFU/day) or Bifidobacterium animalis subsp. lactis UABla-12 (1 10(10) CFU/day …
Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, Lact …
Bifidobacterium animalis subsp. lactis 420 for Metabolic Health: Review of the Research.
Uusitupa HM, Rasinkangas P, Lehtinen MJ, Mäkelä SM, Airaksinen K, Anglenius H, Ouwehand AC, Maukonen J. Uusitupa HM, et al. Nutrients. 2020 Mar 25;12(4):892. doi: 10.3390/nu12040892. Nutrients. 2020. PMID: 32218248 Free PMC article. Review.
In the search for such strains, the effect of Bifidobacterium animalis subsp. lactis 420 (B420) on gut microbiota and metabolic health, and the mechanisms of actions, has been investigated in a variety of in vitro, pre-clinical, and clinical studies. ...
In the search for such strains, the effect of Bifidobacterium animalis subsp. lactis 420 (B420) on gut microbiota and m …
Bifidobacterium animalis subsp. lactis A6 ameliorates bone and muscle loss via modulating gut microbiota composition and enhancing butyrate production.
Chen M, Li Y, Zhai Z, Wang H, Lin Y, Chang F, Ge S, Sun X, Wei W, Wang D, Zhang M, Chen R, Yu H, Feng T, Huang X, Cheng D, Liu J, Di W, Hao Y, Yin P, Tang P. Chen M, et al. Bone Res. 2025 Feb 25;13(1):28. doi: 10.1038/s41413-024-00381-1. Bone Res. 2025. PMID: 40000617 Free PMC article.
Employing dextran sulfate sodium (DSS)-induced gut dysfunction model and wide-spectrum antibiotics (ABX)-treated mice model, our study revealed that gut dysfunction instigates muscle and bone loss, accompanied by microbial imbalances. Importantly, Bifidobacterium animal …
Employing dextran sulfate sodium (DSS)-induced gut dysfunction model and wide-spectrum antibiotics (ABX)-treated mice model, our study revea …
Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial.
Pedret A, Valls RM, Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Moragas A, Martín-Luján F, Ortega Y, Giralt M, Caimari A, Chenoll E, Genovés S, Martorell P, Codoñer FM, Ramón D, Arola L, Solà R. Pedret A, et al. Int J Obes (Lond). 2019 Sep;43(9):1863-1868. doi: 10.1038/s41366-018-0220-0. Epub 2018 Sep 27. Int J Obes (Lond). 2019. PMID: 30262813 Free PMC article. Clinical Trial.
BACKGROUND: The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown. ...
BACKGROUND: The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-ki …
Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes.
Sun B, Ma T, Li Y, Yang N, Li B, Zhou X, Guo S, Zhang S, Kwok LY, Sun Z, Zhang H. Sun B, et al. mSystems. 2022 Apr 26;7(2):e0010022. doi: 10.1128/msystems.00100-22. Epub 2022 Mar 28. mSystems. 2022. PMID: 35343796 Free PMC article. Clinical Trial.
A 6-month randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the added benefits and mechanism of the probiotic strain, Bifidobacterium lactis Probio-M8, in alleviating CAD when given together with a conventional regimen. ...In-d …
A 6-month randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the added benefits and mechanism of the p …
2,468 results